These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27240120)

  • 1. The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa.
    Walensky RP; Borre ED; Bekker LG; Resch SC; Hyle EP; Wood R; Weinstein MC; Ciaranello AL; Freedberg KA; Paltiel AD
    Ann Intern Med; 2016 Sep; 165(5):325-33. PubMed ID: 27240120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid.
    Walensky RP; Borre ED; Bekker LG; Hyle EP; Gonsalves GS; Wood R; Eholié SP; Weinstein MC; Anglaret X; Freedberg KA; Paltiel AD
    Ann Intern Med; 2017 Nov; 167(9):618-629. PubMed ID: 28847013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.
    Smith JA; Sharma M; Levin C; Baeten JM; van Rooyen H; Celum C; Hallett TB; Barnabas RV
    Lancet HIV; 2015 Apr; 2(4):e159-68. PubMed ID: 25844394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When to start antiretroviral therapy in resource-limited settings.
    Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
    Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
    Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
    Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States.
    Borre ED; Hyle EP; Paltiel AD; Neilan AM; Sax PE; Freedberg KA; Weinstein MC; Walensky RP
    J Infect Dis; 2017 Oct; 216(7):798-807. PubMed ID: 29029344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial.
    Thomas R; Probert WJM; Sauter R; Mwenge L; Singh S; Kanema S; Vanqa N; Harper A; Burger R; Cori A; Pickles M; Bell-Mandla N; Yang B; Bwalya J; Phiri M; Shanaube K; Floyd S; Donnell D; Bock P; Ayles H; Fidler S; Hayes RJ; Fraser C; Hauck K;
    Lancet Glob Health; 2021 May; 9(5):e668-e680. PubMed ID: 33721566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study.
    Reddy KP; Gupta-Wright A; Fielding KL; Costantini S; Zheng A; Corbett EL; Yu L; van Oosterhout JJ; Resch SC; Wilson DP; Horsburgh CR; Wood R; Alufandika-Moyo M; Peters JA; Freedberg KA; Lawn SD; Walensky RP
    Lancet Glob Health; 2019 Feb; 7(2):e200-e208. PubMed ID: 30683239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
    Long EF; Stavert RR
    J Gen Intern Med; 2013 Oct; 28(10):1294-301. PubMed ID: 23588668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa.
    Walensky RP; Wood R; Fofana MO; Martinson NA; Losina E; April MD; Bassett IV; Morris BL; Freedberg KA; Paltiel AD;
    J Acquir Immune Defic Syndr; 2011 Jan; 56(1):26-35. PubMed ID: 21068674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National and provincial estimated costs and cost effectiveness of a programme to reduce mother-to-child HIV transmission in South Africa.
    Wilkinson D; Floyd K; Gilks CF
    S Afr Med J; 2000 Aug; 90(8):794-8. PubMed ID: 11022629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
    Ciaranello AL; Doherty K; Penazzato M; Lindsey JC; Harrison L; Kelly K; Walensky RP; Essajee S; Losina E; Muhe L; Wools-Kaloustian K; Ayaya S; Weinstein MC; Palumbo P; Freedberg KA
    AIDS; 2015 Jun; 29(10):1247-59. PubMed ID: 25870982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples.
    Walensky RP; Ross EL; Kumarasamy N; Wood R; Noubary F; Paltiel AD; Nakamura YM; Godbole SV; Panchia R; Sanne I; Weinstein MC; Losina E; Mayer KH; Chen YQ; Wang L; McCauley M; Gamble T; Seage GR; Cohen MS; Freedberg KA
    N Engl J Med; 2013 Oct; 369(18):1715-25. PubMed ID: 24171517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral suppression among pregnant adolescents and women living with HIV in rural KwaZulu-Natal, South Africa: a cross sectional study to assess progress towards UNAIDS indicators and Implications for HIV Epidemic Control.
    Ntombela NP; Kharsany ABM; Soogun A; Yende-Zuma N; Baxter C; Kohler HP; McKinnon LR
    Reprod Health; 2022 May; 19(1):116. PubMed ID: 35550580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress and prospects for the control of HIV and tuberculosis in South Africa: a dynamical modelling study.
    Williams BG; Gupta S; Wollmers M; Granich R
    Lancet Public Health; 2017 May; 2(5):e223-e230. PubMed ID: 29253488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.
    Levison JH; Wood R; Scott CA; Ciaranello AL; Martinson NA; Rusu C; Losina E; Freedberg KA; Walensky RP
    Clin Infect Dis; 2013 Feb; 56(4):587-97. PubMed ID: 23087386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States.
    Long EF; Brandeau ML; Owens DK
    Ann Intern Med; 2010 Dec; 153(12):778-89. PubMed ID: 21173412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study.
    Sharma M; Mudimu E; Simeon K; Bershteyn A; Dorward J; Violette LR; Akullian A; Abdool Karim SS; Celum C; Garrett N; Drain PK
    Lancet HIV; 2021 Apr; 8(4):e216-e224. PubMed ID: 33347810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.
    Paltiel AD; Walensky RP; Schackman BR; Seage GR; Mercincavage LM; Weinstein MC; Freedberg KA
    Ann Intern Med; 2006 Dec; 145(11):797-806. PubMed ID: 17146064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness.
    Bassett IV; Govindasamy D; Erlwanger AS; Hyle EP; Kranzer K; van Schaik N; Noubary F; Paltiel AD; Wood R; Walensky RP; Losina E; Bekker LG; Freedberg KA
    PLoS One; 2014; 9(1):e85197. PubMed ID: 24465503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.